Skip to Content

Karbinal ER Approval History

FDA Approved: Yes (First approved March 28, 2013)
Brand name: Karbinal ER
Generic name: carbinoxamine
Dosage form: Extended-Release Oral Suspension
Company: Tris Pharma, Inc.
Treatment for: Conjunctivitis, Allergic, Allergic Reactions, Allergic Rhinitis, Allergic Urticaria

Karbinal ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis.

Development History and FDA Approval Process for Karbinal ER

DateArticle
Apr  3, 2013Approval FDA Approves Tris Pharma's New Drug Application for Karbinal ER

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide